A list of the Clinical-Scientific Studies for Coriolus Versicolor. • Aoki T, Usuda Y, Miyakoshi H, et al. Low natural killer syndrome: clinical and immunologic features. Nat Immun Cell Growth Regul 1987;6:116-128.
• Chen Z, Yang M, Zhu P. Research and application of the anticancerous mechanism of the purified PSP (PCV). In: Yang Q, Kwok C, eds. PSP International Symposium 1993. Hong Kong: Fudan University Press; 1993:151-152.
• Chu KKW, Ho SS, Chow AHL. Coriolus versicolor a medicinal mushroom with promising immunotherapeutic values. J Clin Pharmacol 2002;42:976-984.
• Ferro A, Boaventura P. Case Study The use of Coriolus supplementation in breast cancer. 2002; presented at the 5th International Symposium on Mushroom Nutrition, University of Westminster, Westminster, UK, June 14th.
• Fisher M, Yang L-X. Anticancer mechanisms and effects of Polysaccharide-K (PSK; Krestin): Implications of immunotherapy with protein-bound polysaccharides. Anticancer Res. 2002;22:1737-1754.
• Gao Y. The evaluation of PSP capsules in clinical pharmacology. In: Yang Q, Kwok C, eds. PSP International Symposium 1993. Hong Kong: Fudan University Press; 1993:209-215.
• Hattori T, Nakajima T, Nakazato H, et al. Postoperative adjuvant immunochemotherapy with mitomycin C, tegafur, PSK and/or OK-
432 for gastric cancer, with special reference to the change in stimulation. Jpn J Surg 1990;20:127-136.
• Hattori T, Niimoto M, Koh T, et al. Postoperative long-term adjuvant
immunochemotherapy with mitomycin-C, PSK and FT-207 in gastric cancer patients. Jpn J Surg 1979;9:110-117.
• Iino Y, Yokoe T, Maemura M, et al. Immunochemotherapies versus chemotherapy as adjuvant treatment after curative resection of operable breast cancer. Anticancer Res 1995;15:2907-2912.
• Ikuzawa M, Matsunaga K, Nishiyama S, et al. Fate and distribution of an antitumor protein bound polysaccharide PSK (Krestin). Intl J
Immunopharmacol 1988;10:415-423.
• Ito K, Nakazato H, Koike A, et al. Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up. Int J Colorectal Dis. 2004;19:157-164.
• Jian Z, Zhang W, Li S. The effect of PSP on LAK cell functions. In: Yang Q, Kwok C, eds. PSP International Symposium 1993. Hong Kong: Fudan University Press; 1993:143-150.
• Jiang X, Huang L, Zhou Y, et al. Subchronic toxicity test of polysaccharopeptide of Yun Zhi (PSP). In: Yang Q, ed. Advanced Research in
PSP, 1999. Hong Kong: Hong Kong Association for Health Care Ltd; 1999:272-284.
• Jong S, Yang X. PSP – a powerful biological response modifier from the mushroom Coriolus versicolor. In: Yang Q, ed. Advanced Research in PSP, 1999. Hong Kong: Hong Kong Association for Health Care Ltd; 1999:16-28.
• Jun L, Mei Z, Yuan C. Reversal of inhibition of reactive oxygen species on respiratory burst of macrophages by polysaccharide from Coriolus versicolor. Int J Immunopharmacol 1993;15:429-33.
• Kanazawa M, Mori Y, Yoshihara K, et al. Effect of PSK on the maturation of dendritic cells derived from human peripheral blood monocytes. Immunology Letters 2004; 91:229-238.
• Kano T, Kumashiro R, Masuda H, et al. Late results of postoperative long-term cancer chemotherapy for the gastric cancer patients subjected to curative resection. Japanese Journal of Surgery 1983;13:112-116.
• Kariya Y, Inoue N, Kihara T, et al. Activation of human natural killer cells by the protein bound polysaccharide PSK independently of interferon and interleukin 2. Immunol Lett 1992;31:241-246.
• Kawa K, Konishi S, Tsujino G, Mabuchi S. Effects of biological response modifiers on childhood ALL being in remission after chemotherapy. Biomedicine and Pharmacotherapy. 1991;45:113-116.
• Ke L. Observation on the substance selected as an accessory treatment for lung cancer. In: Yang Q, Kwok C, eds. PSP International Symposium 1993. Hong Kong: Fudan University Press; 1993:273.
• Ke L, Yao P, Gao Z, et al. An observation on the effects of polysaccharide peptide (PSP) as an accessary treatment for lung cancer. In: Yang Q, ed. Advanced Research in PSP, 1999. Hong Kong: Hong Kong Association for
Health Care Ltd; 1999:331.
• Kenyon J. Observational non-controlled study of Coriolus versicolor supplementation in 30 cancer patients. 2002; presented at the 5th International Symposium on Mushroom Nutrition, University of Westminster, Westminster, UK, June 14th.
• Kidd P. The use of mushroom glucans and proteoglycans in cancer treatment. Alternative Medicine Review 2000;5:4-27.
• Kidd P. Mushroom superfoods and immunoceuticals combat cancer. Total Health magazine 2005;26, Issue 6 (January).
• Kikuchi Y, Kizawa I, Oomori K, et al. Effects of PSK on Interleukin-2 production by peripheral lymphocytes of patients with advanced ovarian carcinoma during chemotherapy. Jpn J Cancer Res 1988;79:125-130.
• Kim F, Sakagami H, Tanuma S, Konno K. Stimulation of interferon-gamma-induced human myelogenous leukemic cell differentiation by high molecular weight PSK subfraction. Anticancer Research 1990;10:55-58.
• Kobayashi H, Matsunaga K, Masahiko F. PSK as a chemopreventive agent. Cancer Epidemiology, Biomarkers & Prevention 1993;2:271-276.
• Kobayashi Y, Kariya K, Saigenji K, Nakamura K. Suppressive effects on cancer cell proliferation of the enhancement of superoxide dismutase [SOD] activity associated with the protein-bound polysaccharide of Coriolus versicolor QUEL. Cancer Biother 1994;9:171-8.
• Kondo M. Immunotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 1994;344:274.
• Kondo M, Torisu M. Evaluation of an anticancer activity of a protein-bound polysaccharide PS-K (Krestin). In: Torisu M, Yoshida T, eds. Basic Mechanisms and Clinical Treatment of Tumor Metastasis. New York: Academic Press; 1985:623-636.
• Liao M, Zhao J. The II stage clinical tests of PSP in the treatment of lung cancer. In: Yan Q, Kwok C, eds. PSP International Symposium 1993. Hong Kong: Fudan University Press; 1993:243-256.
• Liu J, Zhou J. Phase II clinical trial for PSP capsules. In: Yang Q, Kwok C, eds. PSP International Symposium 1993. Hong Kong: Fudan University Press; 1993:183-208.
• Liu J, Zhou J, Liu T. Phase III clinical trial for Yun Zhi polysaccharopeptide (PSP) capsules. In: Yang Q, ed. Advanced Research in PSP, 1999. Hong Kong: Hong Kong Association for Health Care Ltd; 1999:295-303.
• Liu T. Role of PSP in the radiation treatment of esophagus cancer. In: Yang Q, Kwok C, eds. PSP International Symposium 1993. Hong Kong: Fudan University Press; 1993:224-231.
• Liu T. PSP in clinical cancer therapy – a review. In: Yang Q, ed. Advanced Research in PSP, 1999. Hong Kong: Hong Kong Association for Health Care Ltd; 1999:68-75.
• Maehara Y, Moriguchi S, Sakaguchi Y, et al. Adjuvant chemotherapy enhances long-term survival of patients with advanced gastric cancer following curative resection. Journal of Surgical Oncology 1990; 45:169-172.
• Mitomi T, Ogoshi K. Clinical study of PSK as an adjuvant immunochemotherapeutic agent against gastric cancer. Jpn J Cancer
Chemother 1986;13:2532-2537.
• Mitomi T, Tsuchiya S, Iijima N, et al. Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. Dis Colon Rectum 1992;35:123-130.
• Mizutani Y, Yoshida O. Activation by the protein-bound polysaccharide PSK (Krestin) of cytotoxic lymphocytes that act on fresh autologous tumor cells and T24 human urinary bladder transitional carcinoma cell line in
patients with urinary bladder cancer. J Urol 1991;145:1082-1087.
• Monro JA. The use of the medicinal mushroom Coriolus MRL as an immuno-therapeutic agent in the treatment of patients with chronic fatigue syndrome. J Integrative Med. 2004;8:101-108.
• Monro JA. Cytokine TH1 immune response vs cytokine TH2 immune response. Mycology News 2004;1(8):6-7.
• Monro JA. Treatment of cancer with mushroom products. Archives of Environmental Health (Abstract only). 2003;58.
• Morimoto T, Ogawa M, Orita K, et al. Postoperative adjuvant randomised trial comparing chemo-endocrine therapy, chemotherapy and immunotherapy for patients with stage II breast cancer: 5-year results from the Nishinihon cooperative study group of adjuvant chemo-endocrine therapy for breast cancer (ACETBC) of Japan. Eur J Cancer 1996;32A:235-242.
• Nakazato H, Koike A, Saji S, et al. Efficacy of immunochemotherapy as adjuvant treatment after curative resection of gastric cancer. Lancet 1994;343:1122-1126.
• Ng TB. A review of research on the protein-bound polysaccharide (polysaccharopeptide, PSP) from the mushroom Coriolus versicolor (Basidomycetes:Polyporaceae) General Pharmacology 1998;30:1-4.
• Niimoto M, Hattori T, Tamada R, et al. Postoperative adjuvant immunochemotherapy with mitomycin C, futraful and PSK for gastric
cancer. An analysis of data on 579 patients followed for five years. Jpn J Surg
1988;18:681-686.
• Oba K, Teramukai S, Kobayashi M, et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer Immunology and Immunotherapy 2007;56:905-911.
• Ogoshi K, Satou H, Isono K, et al. Possible predictive markers of immunotherapy in esophageal cancer: retrospective analysis of a
randomized study. Cancer Invest 1995;13:363-369.
• Ogoshi K, Miyaji M, Nakamura K, et al. Immunotherapy and combined assay of serum levels of carcinoembryonic antigen and acute phase reactants. Cancer Immunol Immunother. 1998;46:14-20.
• Ohashi Y, Watanabe M, Ikeda M, et al. Regression of metastatic hepatic cancer from gastric cancer by polysaccharide K and UFT administration--a case report. [English abstract only-article in Japanese] Gan To Kagaku Ryoho. 2008;35:2409-12.
• Ohno R, Yamada K, Masaoka T, et al. A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using
a protein-bound polysaccharide preparation. Cancer Immunol Immunother 1984;18:149-154.
• Ohwada S, Ikeya T, Yokomori T, et al. Adjuvant immunochemotherapy with oral Tegafur/Uracil plus PSK in patients with stage II or III colorectal cancer: a randomised controlled study. British J Cancer 2004;90:1003-1010. Comment in: British J Cancer. 2004;91:1220-1; author reply 1221-1223.
• Ohwada S, Kawate S, Ikeya T, et al. Adjuvant therapy with protein-bound polysaccharide K and tegafur/uracil in patients with Stage II or III colorectal cancer: Randomized, controlled trial. Dis Colon Rectum. 2003;46:1060-1068.
• Ohwada S, Ogawa T, Makita F, et al. Beneficial effects of protein-bound polysaccharide K plus tegafur/uracil in patients with stage II or III colorectal cancer: analysis of immunological parameters. Oncology Reports 2006;15:861-868.
• Okudaira Y, Sugimachi K, Inokuchi K, et al. Postoperative long-term immunochemotherapy for esophageal carcinoma. Jpn J Surg 1982;12:249-256.
• Pfeiffer M. Case Study: The clinical use of Coriolus versicolor supplementation in HIV+ patients and the impact on viral load. 2001; presented at the III International Symposium on Mushroom Nutrition, Milan, March 10th, 2001.
• Rotolo G. A Clinical Curiosity: Coriolus versicolor and the treatment of secondary phenomena associated with HIV. 1999;presented at the 10th International Congress of Mucosal Immunology in Amsterdam, June 28th - July 1st.
• Sakagami H, Aoki T. Induction of immunopotentiation activity by a protein bound polysaccharide, PSK (review). Anticancer Res 1991;11:993-1000.
• Shen Q, Shu H, Shen D. PSP will bring hope and life to cancer patients. In: Yang Q, Kwok C, eds. PSP International Symposium 1993. Hong Kong: Fudan University Press; 1993:274-282.
• Sakai T, Yamashita Y, Maekawa T, et al. Immunochemotherapy with PSK and fluoropyrimidines improves long-term prognosis for curatively resected colorectal cancer. Cancer Biother Radiopharm. 2008;23:461-467.
• Sakamoto J. Morita S, Oba K, et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunotherapy 2006; 55:404-411.
• Shi J. PSP for the protection of the tumorous patients during chemotherapy. In: Yang Q, Kwok C, eds. PSP International Symposium 1993. Hong Kong: Fudan University Press; 1993:271-272.
• Shi J, Chen T, Zhao Y. Protective effects of PSP for the patients with gastric cancer during chemotherapy. In: Yang Q, ed. Advanced Research in PSP, 1999. Hong Kong: Hong Kong Association for Health Care Ltd;
1999:329.
• Silva Couto J, Pereira da Silva D. Evaluation of the efficacy of Coriolus versicolor supplementation in HPV lesions (LSIL). 2008; presented at the 19th Portuguese Congress of Obstetrics and Gynecology, Lisbon.
• Sun Z, Lu M, Feng J. The preliminary appraisal of poly-saccharide-peptide (PSP) in malignant and non-malignant diseases. In: Yang Q, Kwok C, eds. PSP International Symposium 1993. Hong Kong: Fudan University
Press; 1993:257-258.
• Sun Z, Yang Q, Fei H. The ameliorative effect of PSP on the toxic and side reactions of chemo-and radiotherapy of cancers. In: Yang Q, ed. Advanced Research in PSP, 1999. Hong Kong: Hong Kong Association for Health Care
Ltd; 1999:304-307.
• Sun T, Zhu Y. The effect of PSP on immune function and living quality in patients receiving chemotherapy for gynecological malignancies. In: Yang Q, ed. Advanced Research in PSP, 1999. Hong Kong: Hong Kong Association
for Health Care Ltd; 1999:308-309.
• Tindall J, Clegg E. A Clinical Curiosity: Coriolus versicolor supplementation in the treatment of Kaposi’s Sarcoma in HIV+ patients. 1999;presented at the 10th International Congress of Mucosal Immunology in Amsterdam, June 28th - July 1st.
• Toi M, Hattori T, Akagi M, et al. Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-year results. Cancer 1992;70:2475-2483.
• Tomochika H, Gouchi A, Okanobu K, et al. The effect and distribution of a protein-bound polysaccharide preparation, PSK (Krestin), intratumorally injected prior to surgery into gastric cancer patients. Acta Med Okayama
1989;43:289-297.
• Torisu M, Hayashi Y, Ishimitsu T, et al. Significant prolongation of disease-free period gained by oral polysaccharide K (PSK) administration after curative surgical operation of colorectal cancer. Cancer Immunol
Immunother 1990;31:261-268.
• Tsang KW, Lam CL, Yan C, et al. Coriolus versicolor polysaccharide peptide slows progression of advanced non-small cell lung cancer. Respir Med 2003; 97:618-24.
• Tsujitani S, Furukawa T, Tamada R, et al. Langerhans cells and prognosis in patients with gastric carcinoma. Cancer 1987;59:501-505.
• Tsujitani S, Kakeji Y, Orita H, et al. Postoperative adjuvant immunochemotherapy and infiltration of dendritic cells for patients with
advanced gastric cancer. Anticancer Res 1992;12:645-648.
• Wang G. Clinical observations of Yun Zhi polysaccharopeptide (PSP) capsule for the supplementary treatment of esophageal, gastric and lung cancer due to radio-chemo-therapy. In: Yang Q, ed. Advanced Research in PSP,
1999. Hong Kong: Hong Kong Association for Health Care Ltd; 1999:333-334.
• Wong CK, Tse PS, Wong EL, et al. Immunomodulatory effects of Yun Zhi and Danshen capsules in healthy subjects- a randomised, double-blind, placebo-controlled crossover study. Int Immunopharmacol. 2004;4:201-211.
• Wu Z, Chen C, Chen Y. Clinical observation of esophageal treatment by radiotherapy together with the oral administration of PSP. In: Yang Q, Kwok C, eds. PSP International Symposium 1993. Hong Kong: Fudan University
Press; 1993:265-268.
• Wu Z, Wang Z. Clinical curative effects observation on NSCLC and esophageal cancer by radiotherapy and chemotherapy combined
with PSP. In: Yang Q, ed. Advanced Research in PSP, 1999. Hong Kong: Hong Kong Association for Health Care Ltd; 1999:326.
• Wu C, Wu J, Sun W. The curative effect of Yun Zhi polysaccharopeptide (PSP) on stomach cancer. In: Yang Q, ed. Advanced Research in PSP, 1999. Hong Kong: Hong Kong Association for Health Care Ltd; 1999:322-323.
• Xie S. The effect of PSP on red-cell immunity– a clinical study on gastric cancer patients. In: Yang Q, Kwok C, eds. PSP International Symposium 1993. Hong Kong: Fudan University Press; 1993:241-242.
• Xu G. The effects of PSP on improving immunity for gastric cancer patients (abstract). In: Yang Q, Kwok C, eds. PSP International Symposium 1993. Hong Kong: Fudan University Press; 1993:263-264.
• Xu G. Phase I clinical test report of PSP capsules. In: Yang, Q, Kwok C, eds. PSP International Symposium 1993. Hong Kong: Fudan University Press; 1993:179-182.
• Yang Q, Kwok C, eds. PSP International Symposium 1993. Hong Kong: Fudan University Press; 1993:257-258.
• Yang QY, Kwok CY, Xu SJ, eds. 1993 PSP International Symposium Anthology of Theses and Abstracts. Shanghai: Fudan University Press; 1993.
• Yang Q, Zhou Y. A protein bound polysaccharide-PSP. In: Yang Q, Kwok C, eds. PSP International Symposium 1993. Hong Kong: Fudan University Press; 1993:22-31.
• Yang Q, Hu Y, Li X, et al. A new biological response modifier substance – PSP. In: Yang Q, Kwok C, eds. PSP International Symposium 1993. Hong Kong: Fudan University Press; 1993:56-72.
• Yang QY. Advanced Research in PSP, 1999. Hong Kong: Hong Kong Association for Health Care Ltd; 1999.
• Yang Q. Yun Zhi polysaccharopeptide (PSP) and the general aspects of its research. In: Yang Q, ed. Advanced Research in PSP, 1999. Hong Kong: Hong Kong Association for Health Care Ltd; 1999:29-38.
• Yang Q. History, present status and perspectives of the study of Yun Zhi
polysaccharopeptide. In: Yang Q, ed. Advanced Research in PSP, 1999. Hong Kong: Hong Kong Association for Health Care Ltd; 1999:5-15.
• Yao W. Prospective randomized trial of radiotherapy plus PSP in the treatment of esophageal carcinoma. In: Yang Q, ed. Advanced Research in PSP, 1999. Hong Kong: Hong Kong Association for Health Care Ltd;
1999:310-313.
• Yao P, Gao Z, Fang S, et al. Evaluation of the subsidiary effects of taking PSP orally on the chemotherapy of stomach cancer. In: Yang Q, Kwok C, eds. PSP International Symposium 1993. Hong Kong: Fudan University Press;
1993:269-270.
• Yeung JH, Chiu LCM. Effect of polysaccharide peptide (PSP) on glutathione and protection against paracetamol-induced hepatotoxicity
in the rat. Methods Find Exp Clin Pharmacol 1994;16:723-729.
• Yokoe T, Iino Y, Takei H, et al. HLA antigen as predictive index for the outcome of breast cancer patients with adjuvant immunochemotherapy with PSK. Anticancer Res 1997;17:2815-2818.
• Yokoe Y. Kato H. Takemura S, et al. Effect of long-term administration of OK-432 (picibanil), PSK (Krestin) and levamisole on immune responses in aged subjects without malignancy. Jap J Clin Oncol. 1979;9:209-214.
• Zhang L. II Stage clinical test report of PSP capsules in the Shu Guang Hospital. In: Yang Q, Kwok C, eds. PSP International Symposium 1993. Hong Kong: Fudan University Press; 1993:269-262.
• Zhong W. Clinical research using PSP and chemotherapy for lung cancer. In: Yang Q, ed. Advanced Research in PSP, 1999. Hong Kong: Hong Kong Association for Health Care Ltd; 1999:332.
More Information on Coriolus Versicolor
Green Medica Coriolus Versicolor is an ultra-high potency dietary supplement, delivering an effective daily intake of the most active immune enhancing nutrients. The glycans are most abundant in the freeze-dried mycelial mass, and many health practitioners recommend the whole mycelium preparation over purified fractions because it retains all of its mushroom glycans. This ensures the most complete immune-enhancing effect.
Green Medica has worked diligently to ensure taht our Coriolus Versicolor is the most powerful immunoceutical, antioxidant, and radio and chemo-protective dietary supplement available anywhere.
BabyBoomer-Healthcare.com
Baby Boomer Magazine is offering this and other quality evidence based nutraceuticals and supplements directly to Baby Boomers at a special negotiated price.
Buy 'Coriolus Versicolor' at a Special Price of $49.95 – 1 months supply
Brain Rescue Specials - Just for Baby Boomer Magazine
BabyBoomer-Magazine.com
1) FREE SHIPPING
Order 1 or more months supply bottle of ‘Coriolus Versicolor’
...
